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Abstract Parathyroid carcinoma is a rare malignancy,
and only accounts for 0.5–2% of cases of primary hyper-
parathyroidism. Less than 10% of parathyroid carcinomas
are non-functional, and as such, they have been rarely
reported in the literature. Importantly, margin status at
resection is related to prognosis, and only a handful of case
reports of non-functional carcinoma note this important
parameter. Here we report the ﬁrst case of non-functional
parathyroid carcinoma with negative margins, and review
the literature on this rare entity. Whether functional or non-
functional, parathyroid carcinoma can often be difﬁcult to
differentiate from benign parathyroid adenoma. While
diagnosis has been based on clinical and histological cri-
teria, recent data concerning the molecular underpinnings
of parathyroid carcinoma may allow for improved accuracy
in distinguishing benign and malignant parathyroid tumors.
Keywords Parathyroid  Carcinoma  Non-functional 
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Clinical Features of Parathyroid Carcinoma
Parathyroid carcinoma is the least common endocrine
malignancy,andaccountedforonly0.005%ofcasesreported
to the National Cancer Database (NCDB) between 1985 and
1995 [1]. Roughly half of cases are diagnosed between ages
45and60 years,butthetumorarisesoverawideagerange.In
the NCDB case series, overall 5- and 10-year survival rates
were 85.5 and 49.5%, respectively. Most patients ([90%)
present with symptoms of hyperparathyroidism, including
severe hypercalcemia, an elevated serum parathyroid hor-
mone (PTH) level, nephrolithiasis or nephrocalcinosis,
osteopenia,gastrointestinaldisturbances,depression,fatigue,
or memory disturbance. Despite this, parathyroid carcinoma
remains a rare cause of primary hyperparathyroidism,
accounting for only 0.5–2% of cases. In comparison, benign
parathyroid adenomas account for approximately 85% of
cases, with diffuse hyperplasia comprising the remainder.
Parathyroid carcinoma has been associated with hyperpara-
thyroidism-jaw tumor (HPT-JT) syndrome, familial isolated
primary hyperparathyroidism, and multiple endocrine neo-
plasiasyndromes(MEN-1andMEN-2A);patientswithHPT-
JT have a 15% prevalence of the tumor [2].
The management of parathyroid carcinoma is primarily
surgical, with en bloc resection of the tumor with involved
adjacent structures being the recommended primary mode
of therapy. Indeed, at least one report indicates that survival
is largely dependent on margin status of the primary
resection [3]. There has been a long debate in the literature
about the effectiveness of adjuvant therapy, largely fueled
by the paucity of cases. However, three recent reports
suggest that adjuvant radiation therapy may reduce tumor
recurrence after resection [3–5]. There is no systematic data
to suggest a role for adjuvant chemotherapy. Despite ther-
apy, between one-third and three-quarters of patients have
recurrence or metastasis of their tumors, causing recurrent
hyperparathyroidism. Re-resection is the accepted therapy
for palliative control of hypercalcemia, but seems to
become less effective with continued iterations [6]. Calc-
imimetic agents, such as cinacalcet, have recently been used
with success in the cases of primary hyperparathyroidism
[7], and may also play a role in palliative management of
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patients who die of disease do so as a result of complica-
tions of hypercalcemia.
While functional parathyroid carcinoma is an uncom-
mon tumor, non-functional parathyroid carcinoma is an
exceedingly rare disease, with less than 20 reported cases
in the last 80 years. As the name implies, patients with
non-functional tumors have normal serum calcium and
PTH levels, and do not present with symptoms of hyper-
calcemia. They typically present with a neck mass, and
patients who die of disease eventually succumb to systemic
tumor burden. Here we report a recent case of non-func-
tional parathyroid carcinoma from our institution necessi-
tating extensive surgery to obtain negative margins, review
the past literature on this rare entity, and discuss recent and
new advances in the diagnosis of both functional and non-
functional parathyroid carcinomas.
Case Summary
The patient is a 59-year-old white man who presented to
his primary care physician in July 2008 with a chief
complaint of dysphagia. His past medical history was
notable for diabetes mellitus type II, hypertension, and
obstructive sleep apnea. Medications included metformin
and amlodipine. He had previously undergone cervical
spine surgery in 2002, and shoulder surgery at an unknown
time. His family history was notable for a half-sister with a
history of breast and gastric cancer, and an uncle with a
history of an unknown head and neck cancer. He is married
and works as a mechanic, rarely used alcohol, and had
previously smoked cigarettes but quit in 1975.
On review of systems, he endorsed dysphagia and
hoarseness, but denied other symptoms. Physical exami-
nation showed a 6-cm ﬁrm mass in the left neck. The mass
extended anteriorly to the left sternocleidomastoid and
inferiorly below the clavicle. Computed tomography, per-
formed at an outside hospital in July 2008, was interpreted
as a 6-cm left thyroid mass. The patient was subsequently
referred to Barnes-Jewish Hospital for ﬁne-needle aspira-
tion of the mass, and evaluation by an otolaryngologist.
Under ultrasonographic guidance, a ﬁne-needle aspira-
tion of the presumed left thyroid lobe tumor was performed
by radiology. A diagnosis of positive for thyroid carcinoma
was returned at the end of July 2008, with a comment that
the cytologic features raised the possibility of a poorly
differentiated or insular variant of thyroid carcinoma; the
cytologic differential diagnosis at that time included fol-
licular variant of papillary thyroid carcinoma (Fig. 1). On
the basis of ﬁndings, excision for examining tissue archi-
tecture was highly recommended.
He was then examined by one of our head and neck
surgeons, who was concerned that the physical and radio-
graphic characteristics of the tumor seemed more aggres-
sive than that seen in the types of thyroid carcinoma given
in the cytologic differential diagnosis. Indeed, magnetic
resonance imaging of the mass, performed at Barnes-Jew-
ish Hospital in early August 2008, showed a large left
cervical mass that displaced the trachea to the right,
extended between the trachea and esophagus in the neck,
and inferiorly into the superior mediastinum (Fig. 2). Also
at that time, the patient underwent an unremarkable labo-
ratory work-up. Of note, the serum calcium was 10.1 mg/dl
(nl = 8.6–10.3 mg/dl), and a serum thyroid function panel,
including thyroid-stimulating hormone, triiodothyronine,
thyroxine, thyroglobulin, anti-thyroglobulin antibody, and
calcitonin, was within normal limits. In light of these
incongruous ﬁndings, the patient was scheduled for a
needle biopsy of the tumor prior to further management.
As in the prior cytology specimen, the needle biopsy
showed a poorly differentiated tumor with morphological
and immunohistochemical features suggestive of neuroen-
docrine differentiation (Fig. 3; see section Pathologic
summary). The diagnosis was initially reported as poorly
differentiated carcinoma with neuroendocrine features; the
differential diagnosis included poorly differentiated/insular
thyroid carcinoma, medullary carcinoma, parathyroid car-
cinoma, carcinoma with thymus-like elements, and neuro-
endocrine carcinoma. The common types of thyroid
Fig. 1 Fine-needle aspirate
smears of non-functional
parathyroid carcinoma (6009).
a Ethanol-ﬁxed, Papanicolaou
stained preparation; b air-dried,
Diff-Quik stained preparation
Head and Neck Pathol (2009) 3:140–149 141carcinoma (papillary and follicular), as well as anaplastic
carcinoma, were ruled out. A subsequent immunostain for
PTH showed diffuse reactivity in tumor cells, and a diag-
nosis of parathyroid carcinoma was rendered. The patient
had no symptoms of hyperparathyroidism, and a serum
intact PTH was 20 pg/ml (nl = 14–72 pg/ml). He was
scheduled for en bloc resection of a non-functional para-
thyroid carcinoma at the beginning of September 2008.
At operation, a large left cervical tumor was found,
intimately involved with the left thyroid lobe. Dissection of
the anterior pretracheal tissues showed tumor adhesion to
the anterior trachea; frozen section analysis of this material
was reported as ‘‘Rare atypical cells; recommend addi-
tional tissue.’’ Dissection of the tumor proceeded posteri-
orly from this point to the tracheoesophageal groove, where
it appeared to invade the trachea and esophagus. At that
point, it was deemed impossible to completely resect the
tumor without sacriﬁcing these structures. Eventually, the
tumor was resected en bloc with the left thyroid lobe and
isthmus, anterior cervical soft tissue, larynx, hypopharynx,
superior esophagus, and ﬁrst eight tracheal rings. A com-
pletion esophagectomy was performed, a gastric conduit
Fig. 2 Pre-operative magnetic
resonance imaging of non-
functional parathyroid
carcinoma. a T2-weighed
transverse section, with
carcinoma (arrowhead)
displacing the trachea (single
arrow) and compressing the
esophagus (double arrow);
b THRIVE sequence frontal
section, with carcinoma
extending across the midline
and into the superior
mediastinum
Fig. 3 Needle core biopsy of non-functional parathyroid carcinoma.
a–c Hematoxylin and eosin-stained sections at a low (209), b
intermediate (1009), and c high magniﬁcation (6009), d–f
representative high-magniﬁcation images (6009) of immunohisto-
chemical stains for d cytokeratin AE1/AE3, e CD56, and f PTH
142 Head and Neck Pathol (2009) 3:140–149was brought up to re-establish continuity, and a jejunos-
tomy tube was placed for feeding. Portions of the manu-
brium, left clavicle, and left ﬁrst rib were also excised to
create access for a mediastinal tracheostomy.
Post-operatively, the patient was extubated and taken to
the cardiothoracic intensive care unit, where he had a rel-
atively uncomplicated course. He was able to transfer to an
observation unit on post-operative day 2, and eventually to
the ﬂoor. He was discharged from the hospital on post-
operative day 18. After discharge, he was seen by our
department of radiation oncology, and initiated adjuvant
radiation therapy in mid-October 2008. This has been
complicated by an episode of hemoptysis requiring inpa-
tient observation about 1 month after initiating therapy. At
the time of this report, the patient is approximately
7 months post-operative and has completed adjuvant
radiotherapy. He tolerates oral intake and exercise, and has
gained 5 pounds in the last few months. Although a com-
puted tomogram of the chest performed February 20, 2009
showed two ill-deﬁned ‘‘ground glass’’ opacities in the
right and left upper lung lobes, he has no deﬁnitive evi-
dence of tumor recurrence. His next scheduled clinical
follow-up is at 9–10 months post-operative.
Pathologic Summary
Aspirate smears of the tumor (Fig. 1) were cellular and com-
posedofcrowdedgroups oftumor cells inacleanbackground.
At high magniﬁcation, individual tumor cells showed round to
ovalnuclei,granularchromatinwithoccasionalsmallnucleoli,
and scant cytoplasm. The groups appeared cohesive and
showed striking uniformity of size and shape.
The needle biopsy material (Fig. 3) showed solid nests of
tumor cells separated by a dense ﬁbrotic stroma, with tumor
cells accounting for about one-quarter of the tissue exam-
ined. As in the cytology preparation, individual tumor cells
were fairly uniform, with round to oval hyperchromatic
nuclei, granular chromatin with inconspicuous nucleoli, and
a small amount of eosinophilic cytoplasm. An extensive
panel of immunohistochemical stains was performed to
characterize the tumor. Tumor cells were strongly and dif-
fusely reactive for cytokeratin AE1/AE3. They also showed
weak or focal reactivity for the neuroendocrine markers
synaptophysin, chromogranin A, and CD56. Stains for thy-
roglobulin, thyroid transcription factor-1, calcitonin, carci-
noembryonic antigen, CD45/leukocyte common antigen,
and CD5 were uniformly non-reactive. As previously men-
tioned, a subsequent send-out immunostain (Gen-Path; Cell
Marque PTH antibody clone MRQ-29, prediluted; antigen
retrieval with Ventana standard CC1 solution at 37C for
32 min) showed diffuse and moderately strong staining for
PTH, leading to the diagnosis of parathyroid carcinoma.
At operation, we received a composite en bloc resection
of tumor and left thyroid lobe, larynx, superior trachea,
hypopharynx, and superior esophagus (Figs. 4 and 5). The
tumor and thyroid lobe was measured as 9.5 9 6.5 9
6.5 cm
3. Gross sections of the specimen showed extension
Fig. 4 En bloc resection of
non-functional parathyroid
carcinoma. a Anterior view of
inked and sectioned gross
specimen, with tumor in relation
to contiguous structures; b low-
magniﬁcation image of tumor
(209); c low-magniﬁcation
image of tumor invading left
thyroid lobe (209); d high-
magniﬁcation image of tumor
(6009)
Head and Neck Pathol (2009) 3:140–149 143of a tongue of tumor into the tracheoesophageal groove, as
suggested by pre-operative imaging (Fig. 2) and operative
ﬁndings. Microscopic sections of the tumor again showed
large solid nests of tumor cells separated by broad bands of
dense ﬁbrosis. At high magniﬁcation, tumor cells showed a
crowded architecture, with focal areas of individual tumor
cell necrosis. No large areas of geographic tumor necrosis
were noted. Nests of tumor extensively involved the thyroid
gland and anterior cervical soft tissues, with extensive
lymphvascular space invasion. In addition, tumor cells
extended through the membranous posterior trachea and
approached the tracheal submucosal glands. Areas of the
anterior trachea, near the area sampled by frozen section,
also showed involvement by tumor. The tumor also
involved the adventitia of the hypopharynx by direct
extension. Although tumor approached the inked resection
margins of the anterior cervical soft tissues, no tumor was
seen at ink, and the sampled resection margins were free of
tumor. A biopsy of the left recurrent laryngeal nerve sub-
mitted for frozen section analysis showed rare atypical
cells, suspicious for carcinoma, only on the permanent
sections. The separately received inferior esophagus and
bones removed for tracheostomy access were free of tumor.
Non-Functional Parathyroid Carcinoma
Table 1 lists the 19 cases of non-functional parathyroid
carcinoma reported in the literature since 1929, including
the present case [8–26]. One case previously considered a
non-functional carcinoma is in fact a non-functional
recurrence of a primary functional parathyroid carcinoma
[27] and so is not considered here. To summarize, most
patients presented in the sixth or seventh decade with a
neck mass, with an age range of 27 to 71 years. All patients
were considered normocalcemic at the time of diagnosis,
and had normal serum levels of PTH in cases where this
was measured. Tumor size was variable, but almost half of
the cases had tumors between 5 and 11 cm in size; in
comparison, the NCDB case series reported a median
tumor size of 3.3 cm [1]. All but one patient received
surgical resection as the primary mode of therapy. The
primary spread of tumor was locoregional invasion into the
thyroid gland, cervical soft tissues, or superior mediasti-
num. Slightly over half of patients had recurrence of their
tumors by the time of case report. Sixteen of 19 patients
were alive at the time of case report, although most cases
reported a relatively short follow-up period; only three of
the cases have data beyond 5 years from the date of initial
therapy.
More striking than the data presented in the above cases,
however, is the data not reported. As noted in the section
‘‘Introduction,’’ the recommended mode of therapy for
parathyroid carcinoma (both functional and non-functional)
is en bloc resection of tumor with involved adjacent
structures, and that overall survival directly correlates with
the margin status of the initial resection [3]. Indeed, our
present case report is the ﬁrst non-functional parathyroid
Fig. 5 En bloc resection of
non-functional parathyroid
carcinoma. a Transverse section
of gross specimen, with tumor
invading tracheoesophageal
groove; b low-magniﬁcation
image of tumor (arrow)
invading membranous posterior
trachea (209); c low-
magniﬁcation image of tumor
(double arrow) invading
lymphvascular space of anterior
trachea (209); d high-
magniﬁcation image of tumor
deposit from previous panel
(4009)
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tion. Although most case reports do not comment on ﬁnal
margin status, we believe it is likely that many of these
cases may have had tumor at or closely approaching the
resection margins. This assumption is based on the fact that
only 4 of the 19 patients received an en bloc or radical
procedure as initial therapy. This may be due to current
therapeutic practices at the time of resection. However, as
listed in Table 1, only 2 of the 19 patients had a pre-
operative diagnosis of parathyroid carcinoma; many more
carried diagnoses that would not have indicated an exten-
sive resection. If not deﬁnitely the case, it is likely that this
diagnostic uncertainty also contributed to the surgical
management of these patients.
To summarize, non-functional parathyroid carcinoma is
a rare endocrine malignancy that presents with mass
symptoms. Due to the paucity of cases and often limited
clinical follow-up, it is difﬁcult to compare survival to
patients with functional parathyroid carcinoma. Non-
functional parathyroid carcinoma is larger at presentation,
appears to be best managed surgically, is often incom-
pletely excised, and shows frequent locoregional recur-
rence and metastasis. It is likely that improvements in the
accuracy of diagnosis will improve the management and
outcomes for patients with both functional and non-func-
tional carcinomas.
Diagnosis of Parathyroid Carcinoma
Clinically, a patient with primary hyperparathyroidism is
most likely to have a parathyroid adenoma. Clues that the
patient may have parathyroid carcinoma include a mark-
edly elevated serum calcium ([14 mg/dl) or PTH ([59 the
upper limit of normal), a palpable neck mass, or hoarseness
(indicating involvement of the recurrent laryngeal nerve)
[28]. Intraoperatively, a ﬁrm grey-white gland with
adherence to, or invasion of, adjacent structures is sug-
gestive of malignancy. Much like other endocrine malig-
nancies, the gold standard for diagnosis of carcinoma is
distant metastasis.
The histological criteria for the diagnosis of parathyroid
carcinoma were published by Schantz and Castleman [29]
in 1973, and are still valid today. They include: sheets or
lobules of tumor cells separated by dense ﬁbrous bands,
mitotic ﬁgures, necrosis, capsular invasion, or vascular
invasion. All of these features are seen in the present case.
However, over 80% of parathyroid carcinomas are well-
differentiated tumors [1], and some of these histologic
features can be seen in atypical parathyroid adenomas [30].
Are there any other criteria to distinguish benign adenomas
from their malignant counterparts?
Recent data have suggested that molecular testing may
be useful in the cases of parathyroid tumors with equivocal
histologic features. The ﬁrst step in this process was the
identiﬁcation of HRPT2, located on chromosome 1q, as the
gene mutated in HPT-JT [31]. Germline mutations were
found in patients with HPT-JT, and sporadic mutations
were also discovered in non-HPT-JT-associated parathy-
roid carcinomas. Additional studies also showed HRPT2
mutations in HPT-JT parathyroid adenomas and carcino-
mas, and sporadic carcinomas, suggesting that the gene
may act as a tumor suppressor, and that its loss may be an
initiating event in carcinogenesis [32, 33]. Expression of
the gene product, termed paraﬁbromin, has also been
investigated in parathyroid neoplasia. Two studies suggest
that sporadic adenomas show expression of paraﬁbromin
by immunohistochemistry, whereas most sporadic carci-
nomas and all HPT-JT-associated parathyroid tumors dis-
play loss of expression, in parallel with the gene mutation
studies [34, 35]. The exact mechanism of carcinogenesis
induced by the loss of paraﬁbromin remains to be eluci-
dated. Recent data suggest that the protein associates with
RNA polymerase, regulates genes involved in cell growth
and survival, acts as a cell cycle regulator, and plays a role
in transducing transcriptional output from the Wnt pathway
[36–40]. In addition to HRPT2, data also show that para-
thyroid carcinomas lose a greater proportion of tumor
suppressor alleles as compared to benign causes of primary
hyperparathyroidism, indicating genomic instability [41].
Testing for loss of these markers may supplement HRPT2/
paraﬁbromin analysis for diagnosis of borderline parathy-
roid neoplasms. The status of HRPT2/paraﬁbromin in
non-functional parathyroid carcinomas has not been
investigated.
Summary
Parathyroid carcinoma is a rare cause of primary hyper-
parathyroidism, and\20 cases of it have been reported in
the literature. In this study, we have reported the ﬁrst case
of non-functional parathyroid carcinoma with negative
surgical margins after en bloc resection. Diagnosis of
parathyroid carcinoma, whether functional or non-func-
tional, is based on a number of clinical and histological
criteria but can be challenging to differentiate from benign
adenoma in many cases. In addition to traditional criteria,
new advances in molecular diagnosis, including evaluation
of HRPT2/paraﬁbromin, may aid in improving diagnostic
accuracy.
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